Trial Profile
An Open-label, Randomised, Multicentre, Single-dose, Parallel Group Trial to Evaluate Pharmacokinetics and Pharmacodynamics of Empagliflozin in Children and Adolescents From 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 26 Jun 2018 Results of an exploratory analysis assessing renal effects within 24 hours of SGLT2 inhibition following a single exposure to empagliflozin in youth with Type 2 diabetes-mellitus presented at the 78th Annual Scientific Sessions of the American Diabetes Association
- 14 Apr 2018 Results published in the Diabetic Medicine
- 22 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.